{"id":1729,"date":"2026-03-09T17:07:00","date_gmt":"2026-03-09T17:07:00","guid":{"rendered":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/?page_id=1729"},"modified":"2026-03-09T17:17:14","modified_gmt":"2026-03-09T17:17:14","slug":"aspro-pd","status":"publish","type":"page","link":"https:\/\/services.nhslothian.scot\/neuroprogressiveanddementianetwork\/aspro-pd\/","title":{"rendered":"ASPro-PD"},"content":{"rendered":"\n
<\/div>
<\/div><\/div>
\n

Ambroxol to Slow Progression in Parkinson Disease <\/h1>\n\n\n\n

ASPro-PD: A Phase III A multi-centre randomised double-blind placebo-controlled trial<\/h3>\n<\/div><\/div><\/div><\/div><\/div>\n\n\n\n
\n
\"ASPro<\/figure>
\n

Project Details<\/strong><\/p>\n\n\n\n

Start Date
January 2026<\/strong><\/p>\n\n\n\n

Status
Open to Recruitment<\/strong><\/p>\n\n\n\n

Principal Investigator
Dr David Breen<\/a><\/p>\n\n\n\n

NDN Study Lead
Emma Fleming<\/a><\/p>\n\n\n\n

Main Research Site
Western General Hospital<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

This clinical trial looks to see if the medication ambroxol<\/strong> can slow or halt the progression of Parkinson\u2019s disease<\/strong>.<\/p>\n\n\n\n

What Happens In This Study?<\/strong><\/p>\n\n\n\n

You will either be given a medicine called ambroxol<\/strong> or a placebo<\/strong> (a dummy pill that looks like the medicine but has no active ingredients). Neither you, nor the research team, will know which group you are in.<\/p>\n\n\n\n

Can I Join This Study?<\/strong><\/p>\n\n\n\n

To take part in this medical trial, you must meet these 8 requirements<\/strong>:<\/p>\n\n\n\n

    \n
  1. Your Diagnosis:<\/strong> A doctor must have confirmed that you have Parkinson\u2019s disease<\/strong>. This needs to have happened within the last 7 years<\/strong>.<\/li>\n\n\n\n
  2. Your Age:<\/strong> You are between 35 and 75 years old<\/strong>.<\/li>\n\n\n\n
  3. Your Symptoms:<\/strong> Your Parkinson\u2019s symptoms should be mild or moderate<\/strong>. A doctor will be able to assess your symptom severity.<\/li>\n\n\n\n
  4. Your Genes:<\/strong> You must know your GBA1 gene status<\/strong>. Your doctor will be able to tell you if this information is available.<\/li>\n\n\n\n
  5. Your Current Medicine:<\/strong> You must have been taking the same Parkinson’s medication for at least the last 3 months<\/strong> without making any big changes to it.<\/li>\n\n\n\n
  6. Your Permission:<\/strong> You must be able to understand what happens in the study and sign a form (called informed consent<\/strong>) to say you agree to join.<\/li>\n\n\n\n
  7. Your Time:<\/strong> You must do your best to attend all your study visits, and follow the rules of the study until it ends.<\/li>\n\n\n\n
  8. Taking the Medicine:<\/strong> You must be willing and able to swallow the trial medication.<\/li>\n<\/ol>\n\n\n\n

    Study Length<\/strong>: 90 weeks (1 year and 10 months)<\/p>\n\n\n\n

    Number of appointments<\/strong>: 7 visits, plus check in phone calls<\/p>\n\n\n\n

    More information on the trial can be found on the Aspro-PD website<\/a>.<\/p>\n<\/div><\/div>\n\n\n\n